Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Grabs Global Rights to RIKEN’s aAVC Technology in Oncology
September 3, 2019
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
- Kowa Gears Up for Glanatec PII Trial in US
September 3, 2019
- Japan Approves Zykadia’s Smaller Film-Coated Tablets
September 3, 2019
- AstraZeneca, Osaka Govt Join Forces on Anti-Allergy Measures
September 3, 2019
- Digital Technologies Hold Key for Japan’s Participation in Global Studies: IQVIA R&D Solutions Head
September 3, 2019
- Astellas Revving Up Digital Transformation Drive, Expands Scope of Data to Derive Values
September 2, 2019
- Daiichi Sankyo’s Pain Drug Tarlige Sweeps Promotion Rankings in June: Impact Track
September 2, 2019
- Kadcyla Filed in Japan for Adjuvant Use in Early Breast Cancer
September 2, 2019
- Osaka Startup Looks to Reposition Polaprezinc/Selenium Combination as NASH Treatment
August 30, 2019
- Xofluza Approved in Taiwan: Shionogi
August 30, 2019
- Hisamitsu Seeks Label Expansion for Fentos Tape
August 30, 2019
- 3 Japan Drug Makers Plow US$65 Million into VC Fund
August 30, 2019
- Eisai to Develop Aussie Firm’s Digital Cognitive Function Self-Assessment Tool in Japan
August 29, 2019
- Nippon Kayaku Skips September Listing for Lilly’s Portrazza
August 29, 2019
- Ono Files BTK inhibitor Tirabrutinib in Japan for Primary CNS Lymphoma
August 29, 2019
- Kyowa Kirin Finally Bags US OK for Parkinson’s Disease Istradefylline
August 29, 2019
- Mitsubishi Tanabe Launches US PIII Study of Continuous SC Liquid Levodopa/Carbidopa for Parkinson’s Disease
August 29, 2019
- Towa, Kyoto iPS Upstart Eye Repositioning of Generic Drug for Alzheimer’s
August 27, 2019
- Amicus Raises Its Hands for Sly Syndrome Drug Development in Japan
August 27, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…